NEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Saundra Pelletier, CEO of Evofem Biosciences.

Mark had the pleasure of recently conducting the Interview with Saundra Pelletier Chief Executive Officer of Evofem Biosciences Inc. (NASDAQ:EVFM). Mr. Roberts diligently focused on questions he thought would be on the minds of most current and potential future shareholders. See interview highlights below.

Access this interview in its entirety at

Evofem Biosciences, Inc. (NASDAQ:EVFM)

Saundra Pelletier, CEO

Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015, and as interim Chair of the Board since November 2021 following the resignation of our former Chair due to health reasons. Ms. Pelletier has been responsible for the company's growth and evolution, and she led Evofem's transition to the public market in January 2018 (NASDAQ:EVFM).

Ms. Pelletier has assembled an impressive team of seasoned pharmaceutical professionals that have a deep understanding of the women's healthcare market and what women want, and she attracted new investor capital. She has also led multiple equity financing rounds which have raised over $491 million.

In her more than 25 years of experience in the pharmaceutical industry, Ms. Pelletier has launched pharmaceutical brands worldwide and expanded indications on female healthcare brands in multiple countries. Her experience includes a comprehensive range of women's healthcare products, cardiovascular, pain management, sleep therapies and medical devices. She has had oversight and accountability for Sales, Marketing, Operations, Medical Affairs, Regulatory Affairs, Manufacturing, Customer Service, Business Development and Strategic Partnerships.

Previously, Ms. Pelletier served as Vice President, Pharmaceuticals at Women First Healthcare, where she raised $40 million in capital. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit, managed worldwide partnerships, negotiated cost saving licensing agreements, assessed country infrastructures, developed commercialization plans and hired full scale teams, including contract sales forces.

In March 2020, she joined the Board of Directors for TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer. She serves as the chair of the Governance/Nomination Committee and is a member of the Audit Committee. She is also a published author, coveted keynote speaker and moderator at key healthcare and political conferences worldwide.

She has appeared at the Harvard School of Public Health, the Davos World Economic Forum, the Clinton Global Initiative, the MAKERS Conference, Women Deliver, the University of Virginia's Darden School of Business, the University of Oregon's Lundquist School of Business and the University of California, San Diego.

She is a trained Climate Reality Advocate and hosted a roundtable session at the International Conference on Climate Change, held in Reykjavik, Iceland. Ms. Pelletier has been profiled by The New York Times, Inc. Magazine, Cosmopolitan, Bustle, CNN, Glamour, Marie Claire, and Vogue. She was named as a New Champion for Reproductive Health by the United Nations Foundation, awarded the Athena San Diego's Pinnacle Award for Life Sciences, named 2019 Business Woman of the Year by the San Diego Business Journal, and named to Inc. Magazine's 2020 Female Founders 100 List.

Interview Highlights:

Traders News Source Editor Mark Roberts covers the actual efficacy of Phexxi, revenue guidance, what will generate the majority of revenue near-term, labeling Phexxi as a deterrent to Chlamydia and Gonorrhea plus much more in this interview.

Access this interview in its entirety at

About Evofem Biosciences

Evofem Biosciences, Inc. (Nasdaq:EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Media Contact

Jack Hirschfield
Evofem Biosciences, Inc.
jhirschfield@evofem.com
(512) 674-5163

Investor Relations Contact

Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775

About Traders News Source (TNS)

Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit:

Media Contact

Traders News Source

Mark Roberts, Senior Editor/Interviewer Editor@TradersNewsSource.com
or Call Paul Lipp, President TNS LLC at +1-810-618-1023

SOURCE: Traders News Source LLC